APLIF - Appili's partner secures additional funding for tularemia vaccine candidate

Appili Therapeutics ([[APLIF]]) has entered into an agreement with Ology Biosciences, under which Ology will manufacture ATI-1701, a novel live attenuated tularemia vaccine candidate.The U.S. Department of Defense has awarded Ology Bioservices $6.3M for ATI-1701 manufacturing and development work under contract.Appili is developing ATI-1701 as a vaccine to combat F. tularensis, he causative agent of tularemia a rare infectious disease that typically attacks the skin, eyes, lymph nodes and lungs.

For further details see:

Appili's partner secures additional funding for tularemia vaccine candidate